| Name | alkaline phosphatase |
|---|---|
| Synonyms | ALP 1; Alkaline phosphatase; ALPG; ALPPL; ALPPL 2; ALPPL2; GCAP; Germ cell alkaline phosphatase… |
| Name | ergocalciferol |
|---|---|
| CAS |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 10327872 | Glerup H, Eriksen EF: deficiency. Ugeskr Laeger. 1999 Apr 26;161(17):2515-21. If the patient also has raised values of PTH or alkaline phosphatase an intramuscular dose of 100,000 IU ergocalciferol pr week for one month is given. |
7(0,0,1,2) | Details |
| 302527 | Petrova EA, Miloserdova AG, Babaskina LI: [Toxic action of ergocalciferol in rickets] . Vopr Pitan. 1977 Mar-Apr;(2):41-3. Tests conducted on albino rats of the Wistar line demonstrated that introduction of large doses of ergocalciferol to animals kept on a -rich diet exhibiting signs of rickets brings about the development in them of specific manifestations of the D-vitamin activity, viz. rising level of and inorganic in the blood serum, lowering of the alkaline phosphatase activity and a greater degree of the soft tissues calcification. |
6(0,0,1,1) | Details |
| 16856326 | Shiau SY, Hwang JY: The dietary requirement of juvenile grass shrimp (Penaeus monodon) for J Nutr. 1994 Dec;124(12):2445-50. In Experiment 1, purified diets with six levels (0, 0.1, 0.5, 2.5, 12.5 and 62.5 mg/kg diet) of supplemental ergocalciferol and were fed to P. monodon (mean weight 0.19 +/- 0.02 g). The feed efficiency ratio and alkaline phosphatase activity generally followed the same pattern as the weight gain. |
2(0,0,0,2) | Details |
| 18463042 | Alzahrani AS, Al Sheef M: Severe primary hyperparathyroidism masked by asymptomatic celiac disease. . Endocr Pract. 2008 Apr;14(3):347-50. Laboratory data (and reference ranges) were as follows: serum calcium, 2.34 mmol/L (2.1 to 2.6); 0.91 mmol/L (0.90 to 1.50); alkaline phosphatase, 421 U/L (40 to 135); albumin, 37 g/L (35 to 45); parathyroid hormone, 874 ng/L (15 to 65); urine 3.76 mmol/d (2.5 to 8); and <13 nmol/L (22 to 116). She was treated with increasing doses of ergocalciferol, and but the serum concentration did not increase substantially (reaching a maximum of 2.70 mmol/L on suprapharmacologic doses of these agents). |
1(0,0,0,1) | Details |
| 18308659 | Camacho PM, Painter S, Kadanoff R: Treatment of adult hypophosphatasia with teriparatide. Endocr Pract. 2008 Mar;14(2):204-8. METHODS: A 75-year-old woman with hypophosphatasia was treated with ergocalciferol and supplements for 2 years. Baseline biochemical values (and reference ranges) were as follows: serum total alkaline phosphatase ranged from 14 to 17 U/L (30 to 110), bone-specific alkaline phosphatase (BSALP) was 5 U/L (14 to 43), serum was elevated at 5.4 mg/dL (2.6 to 4.4), and was high at 250 ng/mL (5 to 30). |
2(0,0,0,2) | Details |
| 11107965 | Glerup H: deficiency among immigrants] . Ugeskr Laeger. 2000 Nov 13;162(46):6196-9. The diagnosis can be tested by three blood tests: serum serum PTH, and serum alkaline phosphatase. If a combination of low and secondary hyperparathyroidism is found, the treatment should be high-dose ergocalciferol or (100,000 IU weekly). |
1(0,0,0,1) | Details |
| 11715587 | Grootjans-Geerts I: [Hypovitaminosis D: a veiled diagnosis] . Ned Tijdschr Geneeskd. 2001 Oct 27;145(43):2057-60. and serum alkaline phosphatase activity may be normal. Treatment with ergocalciferol is effective and cheap. |
1(0,0,0,1) | Details |
| 19661219 | Kalantar-Zadeh K, Kovesdy CP: Clinical outcomes with active versus nutritional compounds in chronic kidney disease. Clin J Am Soc Nephrol. 2009 Sep;4(9):1529-39. Epub 2009 Aug 6. Some opinion-based guidelines recommend administration of such nutritional agents as ergocalciferol or as the first therapy in hyperparathyroidism associated with low circulating levels of 25- (<30 ng/ml) in nondialysis dependent CKD patients. Compared with nutritional agents, active compounds appear to more effectively lower the circulating levels of alkaline phosphatase, a conveniently available biomarker associated with increased mortality and coronary artery calcification in CKD patients. |
1(0,0,0,1) | Details |
| 8865145 | Heikinheimo R, Sievanen H, Jantti P, Maki-Jokela PL, Rajala S, Vuori I: treatment and bone mineral density in the aged. Maturitas. 1996 May;23 Suppl:S77-80. The bone mineral density in the distal forearm and femoral neck did not differ between nine residents (mean age 81.0 years) of an old peoples' home who had received an annual injection of 150,000 IU ergocalciferol during the foregoing 2-7 years (mean 5.1 years) and nine age-, weight- and height-matched control subjects who had subnormal level. The alkaline phosphatase and parathyroid hormone levels were clearly higher when the level was below 10 nmol/1. |
1(0,0,0,1) | Details |
| 17389892 | Hernandez JD, Wesseling K, Boechat MI, Gales B, Salusky IB: Osteomalacia in a hemodialysis patient receiving an active sterol. Nat Clin Pract Nephrol. 2007 Apr;3(4):227-32. INVESTIGATIONS: The patient underwent a physical examination, and his serum levels of alkaline phosphatase, parathyroid hormone, aluminum and (25OH- were determined. MANAGEMENT: Monthly therapy with ergocalciferol and discontinuation of paricalcitol. |
1(0,0,0,1) | Details |
| 12186406 | Hata K, Sugawara F, Ohisa N, Takahashi S, Hori K: Stimulative effects of (22E,24R)-ergosta-7,22-diene-3beta,5alpha,6beta-triol from fruiting bodies of Tricholoma auratum, on a mouse osteoblastic cell line, MC3T3-E1. Biol Pharm Bull. 2002 Aug;25(8):1040-4. Sixteen buffered saline (PBS), 8 boiled PBS, 14 and 12 extracts induced alkaline phosphatase (ALP) activities, an indicator of MC3T3-E1 cell differentiation. To investigate the relationships between the chemical structure and differentiation-inducing activity of the compound, ALP-inducing activities of MC3T3-E1 cells by 1, (2), ergocalciferol (3), cholesta-3beta3,5alpha6beta-triol (4), (5) and (6) were tested. |
1(0,0,0,1) | Details |
| 3877585 | Hodson EM, Evans RA, Dunstan CR, Hills E, Wong SY, Rosenberg AR, Roy LP: Treatment of childhood renal osteodystrophy with or ergocalciferol. Clin Nephrol. 1985 Oct;24(4):192-200. Plasma levels rose while parathyroid hormone and alkaline phosphatase levels fell following both treatments, and were unchanged in non-compliant children. |
1(0,0,0,1) | Details |
| 9062528 | Zeghoud F, Vervel C, Guillozo H, Walrant-Debray O, Boutignon H, Garabedian M: Subclinical deficiency in neonates: definition and response to supplements. Am J Clin Nutr. 1997 Mar;65(3):771-8. To determine the biological criteria for neonatal deficiency, serum parathyroid hormone (PTH), phosphates, and alkaline phosphatase (ALP) activity were measured during the winter-spring period in 80 healthy neonates and their mothers 3-6 d after delivery. A longitudinal 3-mo survey of the serum biology of 52 of these neonates consuming formula was also performed to test the influence of their neonatal status on the effects of two oral ergocalciferol supplements (500 and 1000 IU or 12.5 and 25 micrograms/d). |
1(0,0,0,1) | Details |
| 6989438 | Brooke OG, Brown IR, Bone CD, Carter ND, Cleeve HJ, Maxwell JD, Robinson VP, Winder SM: supplements in pregnant Asian women: effects on status and fetal growth. Br Med J. 1980 Mar 15;280(6216):751-4. In a double-blind trial of supplements in pregnant Asian women (ergocalciferol, 1000 IU/day) was administered to 59 women and placebo to 67 controls during the last trimester. Mothers in the treatment group gained weight faster in the last trimester than those in the control group, and at term they and their infants all had adequate plasma 25-OHD concentrations, Mothers and infants in the control group, however, had low plasma concentrations of 25-OHD and and raised plasma alkaline phosphatase (bone isoenzyme) activity. |
1(0,0,0,1) | Details |
| 18937749 | Rajah J, Jubeh JA, Haq A, Shalash A, Parsons H: Nutritional rickets and z scores for height in the United Arab Emirates: to D or not to D?. Pediatr Int. 2008 Aug;50(4):424-8. The alkaline phosphatase (ALP) was negatively correlated to z scores, implying that higher ALP concentrations predicted severe bone disease (lower z scores). A cohort of patients with nutritional rickets was treated with (2) (ergocalciferol) alone. |
1(0,0,0,1) | Details |
| 11335767 | Carvalho NF, Kenney RD, Carrington PH, Hall DE: Severe nutritional deficiencies in toddlers resulting from health food milk alternatives. Pediatrics. 2001 Apr;107(4):E46. The serum alkaline phosphatase was markedly elevated (1879 U/L), was low (1.7 mg/dL), and was low normal (8.9 mg/dL). The patient was treated with ergocalciferol and supplements. |
1(0,0,0,1) | Details |
| 195455 | Arnaud SB, Matthusen M, Gilkinson JB, Goldsmith RS: Components of in serum of young children in upper midwestern United States. Am J Clin Nutr. 1977 Jul;30(7):1082-6. The relative importance of cholecalciferof and ergocalciferol in maintaining the level in children (1/2 to 6 years old) living in the upper midwestern United States was determined by measurement of total (25-OH-D), its components, and other indices of homeostasis in serum. |
0(0,0,0,0) | Details |